Browse All

Current Filters

CLEAR FILTER x

TITLE

Author:

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Pridopidine for the Treatment of ALS—Results from the Phase 2 Healey ALS Platform Trial

              Author:Shefner, Jeremy   Oskarsson, Bjorn   Cohen, Yael   Chen, Kelly   Leitner, Melanie   Berry, James   Macklin, Eric   Chibnik, Lori   Pothier, Lindsay   Geva, Michal   Goldberg, Paul   Hayden, Michael   Paganoni, Sabrina   Cudkowicz, Merit   

              Session Name:S5: ALS and CMT: New Therapeutic Approaches  

              Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

              Program Number:S5.003  

              Author Institution:Barrow Neurological Institute, Phoenix, AZ  Mayo Clinic, Jacksonville, FL  Prilenia Therapeutics, Kibbutz Yakum, Israel  Accelerating NeuroVentures, LLC, Needham, MA  Massachusetts General Hospital, Boston, MA  Prilenia Therapeutics, Herzlyia, Israel  

              Results from a Phase 2 Clinical Trial of Repeated Intrathecal Autologous Adipose-derived MSCs in ALS

              Author:Staff, Nathan   Oskarsson, Bjorn   Muzyka, Iryna   Madigan, Nicolas   Mester, Carly   Figdore, Daniel   Turner, Michelle   Thuro, Lisa   Osgood, Thomas   Madde, Pranathi   Deeds, Michael   Wiltshire, Timothy   Algeciras-Schimnich, Alicia   Mandrekar, Jayawant   Dietz, Allan   Windebank, Anthony   

              Session Name:S5: ALS and CMT: New Therapeutic Approaches  

              Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

              Program Number:S5.004  

              Author Institution:Mayo Clinic, Rochester, MN  Mayo Clinic Florida, Jacksonville, FL  Mayo Clinic Arizona, Scottsdale, AZ  

              Pre-clinical Antisense Oligonucleotide Treatment of CMT2E in a Human Induced Pluripotent Stem Cell (iPSC)-derived Motor Neuron Model

              Author:Medina, Jessica   Rebelo, Adriana   Jacobs, Elizabeth   Danzi, Matt   Zuchner, Stephan   Saporta, Mario   

              Session Name:S5: ALS and CMT: New Therapeutic Approaches  

              Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

              Program Number:S5.008  

              Author Institution:University of Miami, MIAMI, FL  University of Miami School of Medicine, Miami, FL  

              Potential ASO-based Personalized Treatment for Charcot-Marie-Tooth Disease Type 2S

              Author:Tyner, Christina   Smieszek, Sandra   Przychodzen, Bart   Johnson, Caroline   Polymeropoulos, Christos   Birznieks, Gunther   Polymeropoulos, Mihael   

              Session Name:S5: ALS and CMT: New Therapeutic Approaches  

              Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

              Program Number:S5.009  

              Author Institution:Vanda Pharmaceuticals Inc., Washington, DC  Vanda Pharmaceuticals Inc., Washington, DC, DC  

              Discovering and Rescuing Toxic Autophagy Derangements in CMT4B3 Using a Novel iPSC-derived Peripheral Nervous System Model of MTMR5 Biology

              Author:Chua, Jason   Stumpf, Sarah   Dawson, Valina   Dawson, Ted   

              Session Name:S5: ALS and CMT: New Therapeutic Approaches  

              Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

              Program Number:S5.010  

              Author Institution:Johns Hopkins University, Baltimore, MD  Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD